Clinical Trial Search

Primary: Change in Pain Score — 1.167; 1.58 score on a scale — p=0.3198

Primary: Number of Subjects in Which the Entire Distal Esophagus Can be Visualized Using the Balloon Based Optical Coherence Tomography Screening — 109 Participants

Primary: Pain Unpleasantness During Perceived Control Condition — 54.5; 60.5 units on a scale

Primary: Number of Primary Eyes With Distance Corrected Near Visual Acuity (DCNVA) to 20/40 or Better or Improvement of 2 or More Lines — 288 Primary Eyes — p=0.025

Primary: Maximum Tolerated Dose (MTD) — 10,000,000,000 50% Tissue Culture Infectious Dose

Primary: Seroconversion Rate — 58.93; 64.29; 64.29; 53.57 percentage of participants

Primary: Participants With Treatment-Emergent Adverse Events (TEAE) — 306; 21; 22; 18 Participants

Primary: Hypoglycemia Rescue: Intent-to-Treat Population — 74; 79 Participants

Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants

Primary: Mean Reduction in Office Systolic Blood Pressure at 6 Months — 17.6 mmHg

Primary: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 18.3; 9.6 percentage of participants

Primary: Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall. — 3.17; 3 units on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants

Primary: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz) — 140500; 139300 Hour nano gram per milliliter…

Primary: Number of Participants With Sustained Virological Response (SVR) — 49 Participants